The CHMP recommends approval of lecanemab for the treatment of mild cognitive impairment (MCI) and mild dementia caused by Alzheimer's disease, in adult patients who are heterozygotes (carry one copy) ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

An international collaboration led by RIKEN researchers has discovered how unusual spherical structures form in the brains of ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

At the same time, hypertension “makes it harder for the brain to remove waste products, such as amyloid beta,” a biological ...

IGC-AD1 significantly impacts both amyloid-beta plaques and tau pathology-two critical drivers in Alzheimer's ...

Prothena is evaluating PRX012 — a wholly owned investigational next-generation subcutaneous, single-injection once-monthly antibody delivered subcutaneously targeting a key epitope at the N-terminus ...

In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...

AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...